therapeutics Archives

Radiant Biotherapeutics reaches milestone to advance its new class of therapeutics against complex cancers

Posted on September 11, 2024 (December 12, 2024) by Ricky

September 11, 2024 – FACIT seeded start-up, Radiant Biotherapeutics (“Radiant”), announced the closing of Series A financing to advance the company’s proprietary multi-specific therapeutics for patients with complex cancers. Radiant’s unique multi-valent antibody platform, called Multabody™, generates best-in-class antibodies with superior potency against multiple target sites implicated in heterogenous diseases such as cancers and can potentially improve patient outcome.

FACIT portfolio company HDAX Therapeutics closes seed financing to target CNS cancers and neuropathies

Posted on September 5, 2024 (December 12, 2024) by Ricky

September 5, 2024 – FACIT congratulates HDAX Therapeutics (“HDAX”) on the closing of a seed financing round to develop their best-in-class HDAC therapeutics for the treatment of a serious cancer conditions. Capital from the investor group, which included an investment from FACIT’s Compass Rose Oncology Fund, will empower HDAX to address the debilitating neuropathic pain frequently experienced by patients with cancer.

FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies

Posted on April 25, 2023 (July 24, 2023) by Ricky

April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

Posted on March 23, 2023 (October 20, 2025) by nicole

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.